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Abstract  Objective: To investigate the molecular pathway of the cytotoxic effect of SN-38 
in human cervical cancer cell lines. 
 Methods: Two human cervical cancer cell lines were treated with various 
concentrations of irinotecan for 24–72 hours and the sensitivity was analysed 
using the MTT assay. Apoptosis was further observed through microscopic 
examinations. The protein expression was determined using Western blot 
analysis. 
 
 Results: CaSki cells demonstrated the highest sensitivity to SN-38, whereas 
HeLa cells showed the lowest. In cervical cancer cells, SN-38 induced apoptosis 
through an intrinsic- and extrinsic-pathways. In addition, we showed that SN-38 
downregulated the phosphorylation of Akt-mTOR pathways in CaSki cells, but not 
in HeLa cells. Interestingly, in HeLa cells, which were more suggestive of a resistant 
phenotype, pre-treatment with LY294002 and rapamycin inhibited activation of 
Akt-mTOR signaling and significantly enhanced the sensitivity of HeLa cells to SN-
38. 
 Conclusions: Irinotecan exerts its anti-neoplastic effects on cervical cancer 
cells by inducing apoptosis through caspase-cascade. Inhibition of Akt-mTOR, 
LY294002 and rapamycin, which is targeted to Akt-mTOR pathways, may sensitize 
irinotecan-resistant cervical cancer cells.
 
 Keywords: Akt-mTOR pathways anti-neoplastic drugs, cervix cancer cells, 
LY294002, rapamycin
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Introduction
Carcinoma of the cervix is the second most 
common neoplasm in Indonesian women and 
the second most common neoplasm leading 
to female cancer mortality.1 Furthermore, it is 
also the second most frequently found cancer 
among women in reproductive age between 15–
44 years old.2 It constitutes almost 15,000 new 
cases and 7,500 deaths per annum.2
Cervical cancer treatment depends on  the 
Fédération Internationale de Gynécologie et 
d’Obstétrique (FIGO) staging. Early stadium of 
cervical cancer is generally treated with radical 
operations but up to now there is no fixed 
standard therapy for FIGO stadium Ib-IIa of 
cervical cancer. Cancer within these stadiums can 
be treated with radical operation, radiotherapy, 
surgery-radiotherapy combination, surgery-
anticancer drug combination, or chemotherapy 
although these combination therapy protocols 
may vary. The administration of the  combination 
therapy for each patient is based on many factors 
including age, general condition, and patient’s 
preference to achieve maximum therapy target 
with minimum complications.
The standard surgery for cervical cancer  in 
stadium Ib and IIa is radical hysterectomy with 
pelvic lymphadenectomy. The benefit of surgical 
therapy is the ability to extract primary tumor 
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selection of the most appropriate type of adjuvant 
therapy for the patient. For stadium Ib2 and IIa, 
neoadjuvant chemotherapy is one of several 
adjuvant therapy alternatives applied. The goal 
of this neoadjuvant chemotherapy is to eradicate 
micrometastasis and reduce primary tumor 
volume so the next treatment effectiveness can 
be improved both for surgery and radiotherapy. 
In addition to radiotherapy, chemotherapy is 
the standard treatment for advanced cervical 
cancers. However, the systemic therapy protocol 
for this kind of cervical cancer keeps changing. In 
the past, chemotherapy was used for recurrent 
and persistent cervical cancer, or cervical cancers 
with metastasis. Currently, chemotherapy is the 
primary treatment for cervical cancers with a 
high risk of reccurrency.
The best possible treatment of locally 
advanced cervical cancer is a combination of 
radiation and cisplatin-based chemotherapy. 
Cisplatin-based chemotherapy as the main 
regimen is still the primary choice for advanced, 
metastatic, and recurrent cervical cancers. Even 
with this regimen, the response rate of advanced 
stadium patients was only 23% with limited 
response time.3 From this data, it is suggested 
that conventional treatment methods have 
reached a plateau and, therefore, to overcome 
this problem, finding a good prognostic factor 
and predictor response to chemotherapy might 
be useful.
Irinotecan (CPT-11) and its analog have 
given promising results on many clinical trials. 
SN-38, which is a semi-synthetic derivative 
of camptothecin, is the active metabolite of 
Irinotecan. Like other camptothecin-derivatives, 
SN-38 inhibits topoisomerase I (Topo I), a 
nuclear enzyme needed for replication and 
transcription by unwinding supercoiled DNA.4 
SN-38 interferes with Topo I activity by trapping 
Topo I-DNA cleavage complexes, leading to lethal 
replication-mediated double strand breaks and 
ended with cell death.4 Currently, irinotecan 
is used as a standard therapy for colon cancer 
but not for cervical cancer. Irinotecan specificity 
against cervical cancer needs to be studied. 
Chemotherapeutic agents kill cancer cells 
through interaction with several distinct intra- 
cellular targets, including factors affecting 
cells cycles, apoptosis cell death, and survival 
pathways. Class I phosphatidylinositol 3-kinase 
(PI3K) and its downstream effectors, such as 
Akt and mTOR, have emerged as a prominent 
proliferation and survival pathway. Activation 
of the PI3K/Akt-mTOR pathway has been 
implicated in many human cancers and shown to 
be associated with chemoresistance.5 We have 
previously shown that advanced cervical cancer 
expressed Akt and mTOR and the expression 
of p-mTOR could predict the response to 
neoadjuvants and the survival of the patients 
treated with cisplatin-based neoadjuvant 
chemotherapy.6,7 A therapeutic strategy for 
selectively modulating the expression of a gene 
of interest is the use of inhibitor agents of Akt 
such as LY294002 and inhibitor agents of  mTOR 
such as rapamycin. We assessed whether the 
active form of irinotecan treatment enhanced 
the inhibition of proliferation signals, in this case 
the Akt-mTOR pathway, which led to increase of 
cell death.
Methods
Cell lines and culture conditions
Two human cervical cancer cell lines, the HeLa 
cell line which is an adenoma cell carcinoma with 
human papilloma virus or HPV-18 (+) and CaSki 
cell line which is a squamous cell carcinoma with 
HPV-16 (+), were purchased from the American 
Type Culture Collection (ATCC) (Manassas, VA). 
HeLa cells were maintained in Eagle’s Minimum 
Essential Medium (EMEM) obtained from Sigma 
Chemical Co. (St. Louis, MO), supplemented with 
2 mM L-glutamine, 1.0 mM sodium pyruvate, and 
10% heat-inactivated fetal bovine serum (FBS) 
obtained from Gibco (BRL, Grand Island, NY). 
The CaSki cells were maintained in Rosewell Park 
Memorial Institute-1640 (RPMI-1640) medium 
(Gibco) supplemented with HEPES (Sigma) and 
10% heat-inactivated FBS.
Drugs and cell treatment
Irinotecan was purchased from Wako Pure 
Chemicals (Osaka, Japan) and received as sterile 
lyophilized powder. A stock solution of 5 mg/
mL was made in dimethylsulfoxide (DMSO) and 
stored at 4 °C. Further dilutions were made in 
culture media to reach the desired concentrations 
when the cells obtained approximately 80% 
confluency. The final concentration of DMSO did 
not exceed 0.08%, a concentration that does not 
alter the growth or survival properties of any cell 
type. We used CPT-11 and SN-38 stock of 3 μM 
peak plasma concentration (ppc) with a range of 
9.8 ng/mL–5 μM. LY294002 and rapamycin were 
purchased from Calbiochem (San Diego, CA). For 
LY294002 (25 μM) or rapamycin (100 nm), cells 
were pre-incubated with these inhibitors for 6 
hours (h) prior to irinotecan treatment.
Drug sensitivity assay
Cell proliferation analysis was performed on 
human cervical cancer cell lines in the presence of 
various concentrations of drugs by a colorimetric 
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methyl thiazolyl tetrazolium (MTT) assay. Briefly, 
exponentially growing cells (2x104 cells/well) 
were plated in 96-well plates. After an overnight 
culture, the medium was substituted by a fresh 
medium with different concentrations of drugs. 
At the end of various treatments, 10 μL of a cell-
counting solution (WST-8, Dojindo Labs, Tokyo, 
Japan) was added. After dissolving the crystals 
with 1 N HCl-isopropanol, the absorbance was 
measured at a wavelength of 450 nm using a 
microtiter plate reader (Beckton Dickinson, 
Franklin Lakes, NJ). A value of 100% was assigned 
to untreated control and the concentration of 
drug that reduced the number of viable cells to 
50% after 24 h of exposure (CPI
50
) was derived 
from cell survival plots. All experiments were 
performed in triplicate.
Light microscopy examination
All cells were cultured in a 6-cm plate and 
treated with drugs as described previously. 
Morphological changes were examined at the 
times indicated and photographed using a 
regular phase contrast microscope.
Western blot analysis
Western  blot  analysis was applied as described.5 
Cells were harvested at the time indicated and 
prepared in a buffer (20 mM Tris–HCl, pH 7.6, 1 
mM EDTA, 140 mM NaCl, 1% Nonidet P-40, 1% 
aprotinin, 1 mM phenylmethylsulfonylfluoride, 
and 1 mM sodium vanadate). The concentration 
of the sample protein was determined by 
bicinchoninic acid (BCA) protein assay (Pierce, 
Rockford, IL). Equal amounts of protein (40 μg) 
were subjected to a 5–20% Tris-tricine Ready Gel 
(Bio-Rad, Tokyo, Japan) and then transferred to 
nitrocellulose membrane (Amersham Pharmacia 
Biotech, Buckinghamshire, UK). Membrane was 
blocked with Tris-buffered saline/0.1% Tween 
20 with 5% nonfat dry milk and incubated in 
primary antibodies against caspase-3, caspase-8, 
caspase-9 and PARP (Santa Cruz); phosphorylated 
Akt (p-Akt, Ser473), phosphorylated mTOR 
(p-mTOR, ser2448) and phosphorylated p70 S6 
Kinase (pS6K1,Thr389) from Cell Signaling at 
4 °C overnight. The bands were visualised by a 
chemiluminescence system (Amersham). The 
expression of beta-actin (Sigma) served as a 
loading control. The density of the bands was 
quantified using Quantity One (BioRad).
Statistical analysis
Quantitative experiments were analyzed using 
Student’s t test. The P value was gained from the 
two-sided tests and were considered significant 
when p<0.05.
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Morphological Assessment of HeLa (A) and CaSki Cells (B) in Control Cultures and after 
SN-38 Treatment in Time-dependent Manner Using Phase-contrast Microscopy (200x 
Magnification)
Fig. 1 
 (A)         Control                2 hours               24 hours       36 hours 
 (B)        Control     2 hours     24 hours        36 hours 
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Results
Sensitivity of human cervical cancer cells to CPT-
11 and SN-38 
To investigate the sensitivity of human cervical 
cancer cells to CPT-11 and SN-38, the cells were 
treated for 24–72 h in a medium containing 
various concentrations of drugs. The exposure 
to drugs (9,8 ng/mL–5 μM) produced a dose and 
time dependent cell growth reduction  in HeLa 
and CaSki cells (Fig. 1-2). CaSki cells demonstrated 
a higher sensitivity compared to HeLa. The cell 
proliferation inhibition 50 (CPI
50
) values for 72 h 
treated HeLa were 320 μM, 1.91 μM and 687.5 
nM for CPT-11, SN-38 disolved with medium, 
and SN-38 disolved with pure water (H
2
O), 
respectively. On the other hand, for 72 h treated 
CaSki, the results were 224 μM, 50.8 nM and 18.6 
nM for CPT-11, SN-38 disolved with medium, 
and SN-38 disolved with pure water, respectively 
(Table 1). Based on these results, both HeLa 
and CaSki cells treated in SN-38 disolved with 
pure water were used for further experiments.
Expression and modulation of other apoptosis-
related proteins by SN-38
In this study, it is also observed that SN-38 
treatment had significantly upregulated the 
Table 1 Concentration Proliferation Inhibition 50 (CPI
50
) of HeLa and CaSki Cells to Rinotecan, SN-38 
Disolved with Medium, and SN-38 with Pure Water (H
2
O)
Cell type Irinotecan SN-38 (med) SN-38 (H2O)
HeLa 320 μM (72 h) 1.91 μM (72 h) 687.5 nM (72 h)
CaSki 224 μM (72 h) 50.8 nM (72 h) 18.62 nM (72 h)
Akt–the Mammalian Target of Rapamycin (mTOR) Pathways Inhibition Increases Cervix Cancer Cell 
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The Effect of SN-38 on the Growth Inhibition of HeLa (Left) and CaSki (Right) Cells Using 
MTT Assay. Concentration-and Time-related Inhibition of Cells Growth at 24, 48 and 72 
Hours were Shown
Fig. 2
Table 2 Concentration Proliferation Inhibition (CPI
50
) of HeLa and CaSki Cells to SN-38 Alone, with 
Pre-treatment LY294002 (LY), and Rapamycin (Rap)
Cell type SN-38 LY-SN-38 Rap-SN-38
HeLa 687.5 nM 265.63 nM 181.6 nM
CaSki 18.62 nM 15.68 nM 4.9 nM
LY, LY294002; Rap, rapamycin
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activation of caspase-8, caspase-9 (35 kDa and 
37 kDa), and caspase-3 (19 kDa and 17 kDa) 
followed by the cleavage of its 89 kDa substrate 
protein with PARP as a hallmark of apoptosis in 
CaSki cells (Fig. 3). This was seen as early as 2 
hours and increased in a time dependent manner, 
demonstrating a significant role of SN-38-
induced apoptosis. On the other hand, the  HeLa 
cells show that there are not much modification 
of active forms of caspase-cascade and PARP’s 
expression (it reaches the plateu phase after 2 
hours of treatment) found. These results indicate 
that SN-38 induced apoptosis differently in 
both cervical cancer cells. CaSki cells are more 
sensitive to SN-38 compared to HeLa cells.
SN-38 treatment altered the expression of PI3K/
Akt-signaling proteins
One of the most important survival-signaling 
pathways is mediated by PI3K and its downstream 
targets, such as Akt and mTOR.8 It was recently 
reported that Akt plays an important role in 
determining the chemosensitivity of many 
kinds of cells.9-11 We evaluated the expression 
of these survival signaling proteins in response 
to SN-38 exposure in cervical cancer cells. It 
showed that SN-38 inhibited the activation of 
Akt in CaSki cells in dose and time dependent 
manner as shown by the reduced expression of 
active form or phosphorylated Akt (Ser473; 60 
kDa), phosphorylated mTOR (Ser2448; 289 kDa) 
and phosphorylated p70 S6 Kinase (Thr389; 70 
kDa) (Fig. 4). On the other hand, for HeLa cells, 
there is not much modification of the active 
form Akt (p-Akt), mTOR (p-mTOR) and pS6K1 
expression. These results indicate that SN-
38 downregulated differently in both cervical 
cancer cells. CaSki cells are more sensitive to 
SN-38 treatment compared to HeLa cells. These 
results indicate that the Akt-mTOR pathway 
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SN-38 Induced Apoptosis; Western Blot Analysis of Active Form of Caspase-cascade 
and PARP Expression in HeLa and CaSki Cells Treated with SN-38. The Expression of 
β-actin Served as the Loading Control
  Fig. 3
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might have an important role to maintain the 
survival of CaSki cells in response to SN-38.
Inhibition of Akt-mTOR pathway increases the 
sensitivity of SN-38 induced apoptosis
To confirm whether the Akt-mTOR pathway 
plays a role in response to SN-38, the LY294002 
and rapamycin as pretreatment to irinotecan 
were used. Pre-treatment with LY294002 
and rapamycin significantly enhance the cell 
proliferation inhibition in HeLa cells (p<0.05, 
Table 2, Fig. 5). As in CaSki cells, pre-treatment 
with LY294002 did not significantly enhance the 
cell proliferation inhibition. On the other hand, 
Akt–the Mammalian Target of Rapamycin (mTOR) Pathways Inhibition Increases Cervix Cancer Cell 
Chemosensitivity to Active form of Irinotecan (SN-38) 
(A)
(B)
SN-38 Effect on p-Akt, p-mTOR and p-70S6K1 Western Blot Analysis of Active Form 
Akt-mTOR Pathways in HeLa and CaSki Cells Harvested for the Time Indicated (A) and 
Different Dose (B). β-actin Served as Control
  Fig. 4
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pre-treatment with rapamycin significantly 
enhanced the chemosensitivity of CaSki cells 
to SN-38 (p<0.05, Table 2). To further evaluate 
the effect of pre-treatment with these inhibitor 
agents on apoptosis, an analysis on the 
morphological changes were performed using 
phase contrast microscopy. The results show that 
pre-treatment with rapamycin induced apoptosis 
in most of CaSki cells, which appeared as bright, 
rounded, and detached cells from the dish.
Discussion
Irinotecan, which is one of the anti-neoplastic 
agents with the broadest spectrum, is currently 
used in the treatment of many types of advanced 
cancers, but not in the cervical carcinoma. Until 
now, the prognosis of patients with advanced, 
persistent, or recurrent squamous cell carcinoma 
of the cervix has been poor.1,2 Resistance to 
chemotherapy is the most frequent obstacle 
to effective treatment. Although the molecular 
mechanisms of paclitaxel in the mediation of 
cell death are well characterised, its effects on 
survival signaling remain unclear. This study 
determined the sensitivity of human cervical 
cancer cells to irinotecan (CPT-11) as well as 
its active form (SN-38) and the results from 
the MTT assay showed that CaSki cells had the 
highest sensitivity, whereas HeLa cells was the 
most resistant. Furthermore, an examination on 
whether CPT-11 and SN-38 induced apoptosis in 
human cervical cancer cells was also performed. 
To determine the molecular mechanism that 
mediates the cytotoxic effect of SN-38 in human 
cervical cancer cells, we performed Western blot 
analysis. In this study, it is demonstrated that SN-
38 activated caspase-8, caspase-9, caspase-3 and 
PARP in CaSki cells. These results indicate that in 
sensitive CaSki cells the induction of apoptosis 
by SN-38 might take place through intrinsic and 
extrinsic pathways.
It was recently reported that CPT-11 and SN-
38 activate a serine/threonin protein kinase Akt, 
which is the downstream target of PI3K.10,12 Our 
results demonstrated that SN-38 inhibits the 
activation of Akt in CaSki cells, which were more 
suggestive of a sensitive phenotype, which is 
shown by the downregulation of phosphorylated 
Akt at serine 473, phosphorylated mTOR at 
Ser2448, and phosphorylated p70 S6 Kinase at 
Thr389. Akt-mTOR pathways have the main role 
in promoting cell survival and are frequently 
associated with chemoresistance to cytotoxic 
drugs. The elevation level of phosphorylated 
Akt-mTOR pathways was reported to be 
involved in the mechanism of chemoresistance.13 
Surprisingly, however, in the HeLa cells, which 
were more suggestive of a resistance phenotype, 
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  Fig. 5 Akt-Mtor Inhibitor Enhances Chemosensitivity of Hela (Left) and Caski (Right) Cells to 
Sn-38; Cells Treated with Sn-38 Alone, with or without 25 μM Ly294002 or 100 μM 
Rapamycin Pre-Treatment. The Cells Proliferation Inhibition was Determined by MTT 
Assay
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